---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-24-000038"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T10:47:41.177209+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Keros Q1 net loss widens to $43.1M; cash $442.4M, runway into 2027

## Summary
- Net loss of $43.1M in Q1 2024 vs $35.8M in Q1 2023, driven by higher R&D spending.
- R&D expenses $38.3M (up $7.2M YoY) reflecting pipeline advancement and manufacturing.
- Cash and equivalents $442.4M as of March 31, up from $331.1M at year-end.
- KER-050 Phase 3 MDS trial design discussed with FDA; update expected mid-2024.
- KER-012 TROPOS Phase 2 PAH trial update anticipated in Q2 2024; ATS poster in May.

## SEC filing metadata
- accession: 0001664710-24-000038
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471024000038/0001664710-24-000038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471024000038/kros-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-24-000038
- JSON: https://secwatch.observer/filing/0001664710-24-000038.json
- Plain text: https://secwatch.observer/filing/0001664710-24-000038.txt

## Key facts
- Earnings Releases
  Keros Therapeutics, Inc. reported quarter ended March 31, 2024 results: net income net loss of $43.1 million.
  - Period: quarter ended March 31, 2024
  - Net income: net loss of $43.1 million
  - Result: reported results
  source text: Keros reported a net loss of $43.1 million in the first quarter of 2024 as compared to a net loss of $35.8 million in the first quarter of 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1664710/000166471024000038/0001664710-24-000038-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.